Literature DB >> 2169452

Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats.

S S Lee1, J Marty, J Mantz, E Samain, A Braillon, D Lebrec.   

Abstract

Cardiac responses to catecholamines are known to be attenuated in chronic liver disease. To elucidate the role of beta-adrenergic receptor alteration in this phenomenon, we measured heart rate responsiveness to isoprenaline and myocardial beta-adrenergic receptor-binding characteristics in three groups of rats: those that were sham operated, those that had portal vein stenosis and those that were cirrhotic because of bile duct ligation. Responsiveness to isoprenaline was evaluated in conscious rats by the dose of isoprenaline needed to increase basal heart rate by 50 beats/min and by the maximal heart rate response. beta-Receptor characteristics in heart membranes were derived from 125I-iodocyanopindolol binding data. Compared with sham-operated controls, cirrhotic rats needed a significantly higher dose of isoprenaline to raise basal heart rate by 50 beats/min (102.3 +/- 19.1 vs. 28.3 +/- 11.3 ng/kg) and lower maximal heart rate response (104 +/- 29 vs. 158 +/- 61 beats/min). In addition, myocardial beta-receptor density was significantly lower in cirrhotic rats (26.5 +/- 4.6 vs. 37.5 +/- 10.3 fmol/mg protein) and the dissociation constant was higher (31.6 +/- 17.0 vs. 14.0 +/- 2.5 pmol/L). Analysis of beta 1/beta 2 subpopulations revealed that the decreased total beta-receptor density was entirely due to selective beta 1-receptor down-regulation. beta-Receptor affinity for agonist was not altered in cirrhotic rats. Rats with portal vein stenosis showed no significant differences in either isoprenaline responsiveness or beta-receptor characteristics when compared with controls. These results indicate that beta-adrenergic receptor down-regulation may be responsible for the myocardial hyporesponsiveness to catecholamines observed in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169452     DOI: 10.1002/hep.1840120306

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

Review 1.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

3.  Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids.

Authors:  Ying-Ying Yang; Hongqun Liu; Soon Woo Nam; George Kunos; Samuel S Lee
Journal:  J Hepatol       Date:  2010-05-06       Impact factor: 25.083

Review 4.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.

Authors:  M Huonker; Y O Schumacher; A Ochs; S Sorichter; J Keul; M Rössle
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 7.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 8.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

9.  Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension.

Authors:  Lionel Fizanne; Nicolas Régenet; Jianhua Wang; Frédéric Oberti; Frédéric Moal; Jerôme Roux; Yves Gallois; Sophie Michalak; Paul Calès
Journal:  Hepatol Int       Date:  2008-04-12       Impact factor: 6.047

10.  The cardiac response to exercise in cirrhosis.

Authors:  F Wong; N Girgrah; J Graba; Y Allidina; P Liu; L Blendis
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.